Details

Pokojninsko zavarovanje : diplomsko delo univerzitetnega programa
ID Sinjur, Urška (Author), ID Pevcin, Primož (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (1,08 MB)
MD5: 7554F32E835BF79E1306C3236374CD25
PID: 20.500.12556/rul/673d1a15-866e-4f74-9bcc-22a39e595669

Language:Slovenian
Keywords:pokojnine, pokojninski skladi, pokojninsko zavarovanje, Slovenija, diplomske naloge
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[U. Sinjur]
Year:2009
Number of pages:IV, 58 str.
PID:20.500.12556/RUL-2459 This link opens in a new window
UDC:368.914(497.4)(043.2)
COBISS.SI-ID:3267246 This link opens in a new window
Publication date in RUL:11.07.2014
Views:4213
Downloads:533
Metadata:XML DC-XML DC-RDF
:
SINJUR, Urška, 2009, Pokojninsko zavarovanje : diplomsko delo univerzitetnega programa [online]. Bachelor’s thesis. Ljubljana : U. Sinjur. [Accessed 25 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=2459
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
  4. Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
  5. Diabetes mellitus and physical activity
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back